Green Pine Capital Partners appeared to be the VC, which was created in 2000. The leading representative office of defined VC is situated in the Shenzhen. The company was established in Asia in China.
The important activity for fund was in 2018. Speaking about the real fund results, this VC is 18 percentage points more often commits exit comparing to other organizations. The typical startup value when the investment from Green Pine Capital Partners is more than 1 billion dollars. The common things for fund are deals in the range of 50 - 100 millions dollars. The fund is generally included in 2-6 deals every year.
The typical case for the fund is to invest in rounds with 2-3 participants. Despite the Green Pine Capital Partners, startups are often financed by Initial Capital, IDG Capital, FH Capital. The meaningful sponsors for the fund in investment in the same round are Lilly Asia Ventures, Yunqi Partners, Ventech China. In the next rounds fund is usually obtained by Warmsun Holding Group, Taishan Invest AG, Lilly Asia Ventures.
The overall number of key employees were 3.
The fund has no specific favorite in a number of founders of portfolio startups. When startup sums 3 or 4 of the founder, the probability for it to get the investment is little. Moreover, a startup needs to be at the age of 2-3 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight UBTech Robotics, Yaoshibang, MGI Tech. For fund there is a match between the country of its foundation and the country of its the most frequent investments - China. We can highlight the next thriving fund investment areas, such as Biotechnology, Pharmaceutical.
Related Funds
Funds with similar focus
Notable deals
Company | Industry | Round Size | Date | Investors | Location |
Neurogin | 23 Aug 2024 | Chengdu, Sichuan, China | |||
Jiangxing Intelligence | 10 Jun 2024 | Xuanwu District, Jiangsu, China | |||
Baisios | 01 Nov 2023 | Fengtai, Beijing, China | |||
Youyun | $30M | 15 Sep 2023 | Hangzhou, Zhejiang, China | ||
Guorui Xiechuang | $15M | 25 May 2023 | Shenzhen, Guangdong, China | ||
Shenzhen 01 Life Science and Technology | $15M | 21 Apr 2023 | Shenzhen, Guangdong, China | ||
Ruitai Biotechnology | $13M | 09 Mar 2023 | Ningbo, Zhejiang, China | ||
Neuracle | 16 Dec 2022 | China, Wuwei, China | |||
Readline | $46M | 09 Dec 2022 | Futian District, Guangdong Province, China |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Latest deals
Company | Industry | Round Size | Date | Investors | Location |
Neurogin | 23 Aug 2024 | Chengdu, Sichuan, China | |||
Jiangxing Intelligence | 10 Jun 2024 | Xuanwu District, Jiangsu, China | |||
Baisios | 01 Nov 2023 | Fengtai, Beijing, China | |||
Youyun | $30M | 15 Sep 2023 | Hangzhou, Zhejiang, China | ||
Guorui Xiechuang | $15M | 25 May 2023 | Shenzhen, Guangdong, China | ||
Shenzhen 01 Life Science and Technology | $15M | 21 Apr 2023 | Shenzhen, Guangdong, China | ||
Ruitai Biotechnology | $13M | 09 Mar 2023 | Ningbo, Zhejiang, China | ||
Neuracle | 16 Dec 2022 | China, Wuwei, China | |||
Readline | $46M | 09 Dec 2022 | Futian District, Guangdong Province, China |